The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide CDMO Services Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Small Molecule CDMO
1.2.3 Macro-molecular CDMO
1.3 Market by Application
1.3.1 Global Peptide CDMO Services Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Clinical Treatment
1.3.3 Medical Research
1.3.4 Commercial Production
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide CDMO Services Market Perspective (2018-2029)
2.2 Peptide CDMO Services Growth Trends by Region
2.2.1 Global Peptide CDMO Services Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Peptide CDMO Services Historic Market Size by Region (2018-2023)
2.2.3 Peptide CDMO Services Forecasted Market Size by Region (2024-2029)
2.3 Peptide CDMO Services Market Dynamics
2.3.1 Peptide CDMO Services Industry Trends
2.3.2 Peptide CDMO Services Market Drivers
2.3.3 Peptide CDMO Services Market Challenges
2.3.4 Peptide CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide CDMO Services Players by Revenue
3.1.1 Global Top Peptide CDMO Services Players by Revenue (2018-2023)
3.1.2 Global Peptide CDMO Services Revenue Market Share by Players (2018-2023)
3.2 Global Peptide CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peptide CDMO Services Revenue
3.4 Global Peptide CDMO Services Market Concentration Ratio
3.4.1 Global Peptide CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide CDMO Services Revenue in 2022
3.5 Peptide CDMO Services Key Players Head office and Area Served
3.6 Key Players Peptide CDMO Services Product Solution and Service
3.7 Date of Enter into Peptide CDMO Services Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide CDMO Services Breakdown Data by Type
4.1 Global Peptide CDMO Services Historic Market Size by Type (2018-2023)
4.2 Global Peptide CDMO Services Forecasted Market Size by Type (2024-2029)
5 Peptide CDMO Services Breakdown Data by Application
5.1 Global Peptide CDMO Services Historic Market Size by Application (2018-2023)
5.2 Global Peptide CDMO Services Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Peptide CDMO Services Market Size (2018-2029)
6.2 North America Peptide CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Peptide CDMO Services Market Size by Country (2018-2023)
6.4 North America Peptide CDMO Services Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide CDMO Services Market Size (2018-2029)
7.2 Europe Peptide CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Peptide CDMO Services Market Size by Country (2018-2023)
7.4 Europe Peptide CDMO Services Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide CDMO Services Market Size (2018-2029)
8.2 Asia-Pacific Peptide CDMO Services Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Peptide CDMO Services Market Size by Region (2018-2023)
8.4 Asia-Pacific Peptide CDMO Services Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide CDMO Services Market Size (2018-2029)
9.2 Latin America Peptide CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Peptide CDMO Services Market Size by Country (2018-2023)
9.4 Latin America Peptide CDMO Services Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide CDMO Services Market Size (2018-2029)
10.2 Middle East & Africa Peptide CDMO Services Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Peptide CDMO Services Market Size by Country (2018-2023)
10.4 Middle East & Africa Peptide CDMO Services Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Incyte
11.1.1 Incyte Company Detail
11.1.2 Incyte Business Overview
11.1.3 Incyte Peptide CDMO Services Introduction
11.1.4 Incyte Revenue in Peptide CDMO Services Business (2018-2023)
11.1.5 Incyte Recent Development
11.2 Gliead
11.2.1 Gliead Company Detail
11.2.2 Gliead Business Overview
11.2.3 Gliead Peptide CDMO Services Introduction
11.2.4 Gliead Revenue in Peptide CDMO Services Business (2018-2023)
11.2.5 Gliead Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Detail
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Peptide CDMO Services Introduction
11.3.4 Boehringer Ingelheim Revenue in Peptide CDMO Services Business (2018-2023)
11.3.5 Boehringer Ingelheim Recent Development
11.4 Vertex
11.4.1 Vertex Company Detail
11.4.2 Vertex Business Overview
11.4.3 Vertex Peptide CDMO Services Introduction
11.4.4 Vertex Revenue in Peptide CDMO Services Business (2018-2023)
11.4.5 Vertex Recent Development
11.5 Mirati Therapeutics
11.5.1 Mirati Therapeutics Company Detail
11.5.2 Mirati Therapeutics Business Overview
11.5.3 Mirati Therapeutics Peptide CDMO Services Introduction
11.5.4 Mirati Therapeutics Revenue in Peptide CDMO Services Business (2018-2023)
11.5.5 Mirati Therapeutics Recent Development
11.6 AMPAC
11.6.1 AMPAC Company Detail
11.6.2 AMPAC Business Overview
11.6.3 AMPAC Peptide CDMO Services Introduction
11.6.4 AMPAC Revenue in Peptide CDMO Services Business (2018-2023)
11.6.5 AMPAC Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Peptide CDMO Services Introduction
11.7.4 Pfizer Revenue in Peptide CDMO Services Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Polypeptide
11.8.1 Polypeptide Company Detail
11.8.2 Polypeptide Business Overview
11.8.3 Polypeptide Peptide CDMO Services Introduction
11.8.4 Polypeptide Revenue in Peptide CDMO Services Business (2018-2023)
11.8.5 Polypeptide Recent Development
11.9 Bachem
11.9.1 Bachem Company Detail
11.9.2 Bachem Business Overview
11.9.3 Bachem Peptide CDMO Services Introduction
11.9.4 Bachem Revenue in Peptide CDMO Services Business (2018-2023)
11.9.5 Bachem Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Peptide CDMO Services Introduction
11.10.4 Merck Revenue in Peptide CDMO Services Business (2018-2023)
11.10.5 Merck Recent Development
11.11 Asymchem
11.11.1 Asymchem Company Detail
11.11.2 Asymchem Business Overview
11.11.3 Asymchem Peptide CDMO Services Introduction
11.11.4 Asymchem Revenue in Peptide CDMO Services Business (2018-2023)
11.11.5 Asymchem Recent Development
11.12 Zhejiang Jiuzhou Pharmaceutical
11.12.1 Zhejiang Jiuzhou Pharmaceutical Company Detail
11.12.2 Zhejiang Jiuzhou Pharmaceutical Business Overview
11.12.3 Zhejiang Jiuzhou Pharmaceutical Peptide CDMO Services Introduction
11.12.4 Zhejiang Jiuzhou Pharmaceutical Revenue in Peptide CDMO Services Business (2018-2023)
11.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Development
11.13 Sinopep
11.13.1 Sinopep Company Detail
11.13.2 Sinopep Business Overview
11.13.3 Sinopep Peptide CDMO Services Introduction
11.13.4 Sinopep Revenue in Peptide CDMO Services Business (2018-2023)
11.13.5 Sinopep Recent Development
11.14 Frontier Biotechnologies
11.14.1 Frontier Biotechnologies Company Detail
11.14.2 Frontier Biotechnologies Business Overview
11.14.3 Frontier Biotechnologies Peptide CDMO Services Introduction
11.14.4 Frontier Biotechnologies Revenue in Peptide CDMO Services Business (2018-2023)
11.14.5 Frontier Biotechnologies Recent Development
11.15 JYMed
11.15.1 JYMed Company Detail
11.15.2 JYMed Business Overview
11.15.3 JYMed Peptide CDMO Services Introduction
11.15.4 JYMed Revenue in Peptide CDMO Services Business (2018-2023)
11.15.5 JYMed Recent Development
11.16 Chengdu Shengnuo Biotechnology
11.16.1 Chengdu Shengnuo Biotechnology Company Detail
11.16.2 Chengdu Shengnuo Biotechnology Business Overview
11.16.3 Chengdu Shengnuo Biotechnology Peptide CDMO Services Introduction
11.16.4 Chengdu Shengnuo Biotechnology Revenue in Peptide CDMO Services Business (2018-2023)
11.16.5 Chengdu Shengnuo Biotechnology Recent Development
11.17 Shanghai Soho-Yiming Pharmaceuticals
11.17.1 Shanghai Soho-Yiming Pharmaceuticals Company Detail
11.17.2 Shanghai Soho-Yiming Pharmaceuticals Business Overview
11.17.3 Shanghai Soho-Yiming Pharmaceuticals Peptide CDMO Services Introduction
11.17.4 Shanghai Soho-Yiming Pharmaceuticals Revenue in Peptide CDMO Services Business (2018-2023)
11.17.5 Shanghai Soho-Yiming Pharmaceuticals Recent Development
11.18 Chinese Peptide Company
11.18.1 Chinese Peptide Company Company Detail
11.18.2 Chinese Peptide Company Business Overview
11.18.3 Chinese Peptide Company Peptide CDMO Services Introduction
11.18.4 Chinese Peptide Company Revenue in Peptide CDMO Services Business (2018-2023)
11.18.5 Chinese Peptide Company Recent Development
11.19 Ambio Pharmaceuticals
11.19.1 Ambio Pharmaceuticals Company Detail
11.19.2 Ambio Pharmaceuticals Business Overview
11.19.3 Ambio Pharmaceuticals Peptide CDMO Services Introduction
11.19.4 Ambio Pharmaceuticals Revenue in Peptide CDMO Services Business (2018-2023)
11.19.5 Ambio Pharmaceuticals Recent Development
11.20 Zhejiang Peptites Biotech
11.20.1 Zhejiang Peptites Biotech Company Detail
11.20.2 Zhejiang Peptites Biotech Business Overview
11.20.3 Zhejiang Peptites Biotech Peptide CDMO Services Introduction
11.20.4 Zhejiang Peptites Biotech Revenue in Peptide CDMO Services Business (2018-2023)
11.20.5 Zhejiang Peptites Biotech Recent Development
11.21 STA Pharmaceutical
11.21.1 STA Pharmaceutical Company Detail
11.21.2 STA Pharmaceutical Business Overview
11.21.3 STA Pharmaceutical Peptide CDMO Services Introduction
11.21.4 STA Pharmaceutical Revenue in Peptide CDMO Services Business (2018-2023)
11.21.5 STA Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details